Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.
Adicet Bio, Inc. reported that President & CEO Chen Schor received a grant of stock options representing the right to buy 468,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.
This award is compensation-related and not an open-market share purchase or sale. The filing notes that one forty-eighth of the options vest each month over 48 months from the grant date, contingent on Mr. Schor continuing his service with the company.
Adicet Bio Chief Medical Officer Julia D. Maltzman was granted stock options covering 72,555 shares of Common Stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. This is a compensation-related award rather than an open-market share purchase.
The filing shows these are held directly and represent 72,555 option shares following the transaction. According to the terms, one forty-eighth of the options vest monthly over 48 months from the grant date, as long as she continues her service with the company.
Adicet Bio, Inc. reported that Chief Technology Officer Don Healey received a grant of stock options covering 43,361 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. According to the terms, 1/48th of the options vest on each of the 48 monthly anniversaries of the grant date, as long as he continues his service with the company. This is a compensation-related award rather than an open-market share purchase.
Adicet Bio, Inc. Chief Scientific Officer Aftab Blake received a grant of stock options to acquire 72,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.
According to the vesting terms, 1/48th of the options vest on each monthly anniversary over the next forty-eight months, as long as Blake continues a service relationship with the company. This is a compensation-related award, not an open-market purchase or sale, and it brings Blake’s directly held option position in this grant to 72,555 derivative securities.
Adicet Bio, Inc. files a shelf registration to offer up to $250,000,000 of common stock, preferred stock, debt securities, warrants and/or units, to be sold from time to time in one or more offerings.
The shelf permits offerings in various combinations and will be accompanied by prospectus supplements that specify amounts, prices and terms. The company notes Nasdaq listing under the symbol ACET and cites a March 11, 2026 closing price of $7.47 per share.
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Its lead candidate, prula-cel, targets CD20 and is in an ongoing Phase 1 program across lupus nephritis, systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis and other autoimmune indications.
The FDA has granted Fast Track designations for prula-cel in relapsed/refractory class III or IV lupus nephritis, refractory SLE with extrarenal involvement and systemic sclerosis, and recently allowed outpatient dosing for lupus nephritis and SLE. Adicet plans a potential pivotal study in lupus nephritis, or lupus nephritis and SLE, starting in the second half of 2026, subject to regulatory clearance.
The company is also advancing ADI-212 for metastatic castration-resistant prostate cancer, aiming to file in the third quarter of 2026 and begin enrollment in the fourth quarter of 2026. A 1-for-16 reverse stock split was effected in December 2025, and as of March 10, 2026, 9,596,407 common shares were outstanding.
Adicet Bio reported continued investment in its pipeline alongside steady operating losses for the quarter and year ended December 31, 2025. In the fourth quarter, research and development expenses were $25.0 million and general and administrative costs were $6.9 million, leading to a net loss of $30.5 million, or $2.94 per share.
For full-year 2025, R&D spending was $99.1 million and G&A was $23.0 million, resulting in a net loss of $116.8 million, or $16.95 per share. Cash, cash equivalents and short-term investments totaled $158.5 million at year-end, and the company expects this to fund operations into the second half of 2027.
Operationally, Adicet highlighted strong enrollment in its Phase 1 autoimmune trial of prulacabtagene leucel (prula-cel), with clinical updates planned in the first and second halves of 2026, and FDA alignment enabling outpatient dosing for lupus nephritis and systemic lupus erythematosus. A Phase 1 study in treatment-refractory rheumatoid arthritis is underway, with another update expected in the second half of 2026.
The company is also advancing ADI-212 for metastatic castration-resistant prostate cancer, planning a regulatory filing in the third quarter of 2026 and expecting Phase 1 enrollment to begin in the fourth quarter of 2026, subject to regulatory clearance.
Adicet Bio reported an updated ownership filing showing that RA Capital Management and affiliated entities beneficially own 960,237 shares of Adicet Bio common stock. This represents approximately 9.99% of the company’s outstanding shares as of December 31, 2025, just after a 16-for-1 reverse stock split.
The RA Capital Healthcare Fund directly holds 948,249 shares plus pre-funded warrants exercisable for up to 1,152,833 additional shares. However, a “Beneficial Ownership Blocker” in the warrants prevents exercises that would push the group’s stake above 9.99%, so only 11,988 warrant shares are currently counted toward beneficial ownership.
RA Capital serves as investment adviser to the fund and may be deemed a beneficial owner for reporting purposes. The filing states that the securities were not acquired to change or influence control of Adicet Bio and that several reporting persons disclaim beneficial ownership except for meeting disclosure obligations.
Adicet Bio, Inc. shareholder Tang Capital Management and affiliated entities report beneficial ownership of 6,158 common shares, representing about 0.1% of the company’s outstanding common stock. The filing attributes shared voting and dispositive power over these shares to Tang Capital Management, Kevin Tang, and Tang Capital Partners International, LP.
The percentage is based on 9,578,474 Adicet Bio common shares outstanding, after giving effect to a one‑for‑sixteen reverse stock split effective December 30, 2025. The reporting persons certify that the securities are not held for the purpose of changing or influencing control of Adicet Bio.